However, the Commission found that the transaction – as originally notified – would have raised competition concerns for 15 pharmaceuticals markets in the Czech Republic, Slovakia, Romania, Bulgaria, Hungary and Estonia.
Siiski leidis komisjon, et tehing – nagu sellest algselt teatati – oleks tekitanud konkurentsiprobleeme 15 farmaatsiatoodete turul Tšehhi Vabariigis, Slovakkias, Rumeenias, Bulgaarias, Ungaris ja Eestis.